Diligence memo · auto-generated · as of July 2, 2026
Eyenovia, Inc.
Eyenovia, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Eyenovia, Inc. operates in Pharmaceuticals, based in LAGUNA HILLS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Eyenovia, Inc. has raised $66M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $50M on 2025-06-20.
Most recent recorded round closed around 2025-06-20.
Valuation (modeled)modeled
Provath models Eyenovia, Inc. at approximately $313M (range $162M–$416M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.08× the median modeled value of Series C Pharmaceuticals companies in 2025–2027 (26 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 36 months.
Last raise 12 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 8.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: BlossomHill Therapeutics, Inc., Rivus Pharmaceuticals, Inc., Sparrow Pharmaceuticals, Inc., Arthrosi Therapeutics, Inc., Altesa BioSciences, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.